Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions.
Gene-editing biotech Editas Medicine Inc
Deal Watch: Editas, BlueRock Ink Cross-Licensing Technology Collaboration
Combining Editas’ CRISPR gene-editing technology with BlueRock’s pluripotent stem cell capabilities, the companies hope to leverage each other to create novel gene therapies for cancer, neurological, cardiovascular and autoimmune diseases.
More from Deals
• By
The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.
• By
Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.
• By
Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
More from Business
• By
The sector is continuing to show resilience despite financial and market challenges.
• By
Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.
• By
The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.